-
Jan 17, 2025 | 
pharmaceutical-technology.com | Eve Thomas
The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential. Pfizer’s virtual lung oncology diagnostics laboratory, developed by Cassette Group. Credit: Cassette Group. The metaverse has faded from buzzword to buzzkill, and the hype that once gripped industries has been quietly brushed under the carpet – or so it may seem. The developing technology was worth $48bn in 2022, and growth is still anticipated.
-
Jan 17, 2025 | 
medicaldevice-network.com | Eve Thomas
The metaverse has faded from buzzword to buzzkill, and the hype that once gripped industries has been quietly brushed under the carpet – or so it may seem. The developing technology was worth $48bn in 2022, and growth is still anticipated. In 2023, GlobalData forecast that the technology would be worth $400bn by 2030 despite acknowledging that “the theme has struggled to live up to the excessive hype that built up in 2021 and early 2022”. GlobalData is the parent company of Medical Device Network.
-
Jan 15, 2025 | 
clinicaltrialsarena.com | Eve Thomas
Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncological pipeline at the company.
-
Jan 15, 2025 | 
pharmaceutical-technology.com | Eve Thomas
Incyte announced plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GVHD. The launches reportedly represent a potential $1bn in incremental revenues for Incyte by 2029. Credit: SOPA Images / Getty Images. Incyte CEO Hervé Hoppenot has promised investors that 2025 will be “a year that will be full of many defining catalysts” for the company.
-
Jan 14, 2025 | 
clinicaltrialsarena.com | Eve Thomas
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor dual agonist HRS9531. The multi-centre, randomised, double-blind, placebo-parallel-controlled, Phase II trial (NCT06054698) took place in China. It included 61 patients randomised in a 4:1 ratio, amounting to 49 patients receiving HRS9531.
-
Jan 13, 2025 | 
clinicaltrialsarena.com | Eve Thomas
Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – onasemnogene abeparvovec (OAV101 IT) – which could become available to a broader patient population. This is following positive results from Novartis’ Phase III STEER study (NCT05089656), which met its primary endpoint when testing the intrathecal formulation of the drug.
-
Jan 10, 2025 | 
pharmaceutical-technology.com | Eve Thomas
GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033. Women accounted for approximately 73% of total prevalent Alzheimer’s cases in 2023. Credit: Antonio Marca / Shutterstock.
-
Jan 10, 2025 | 
pharmaceutical-technology.com | Eve Thomas
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January. The FDA headquarters at White Oak Campus. Credit: Tada Images / Shutterstock. The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald Trump’s inauguration on 20 January.
-
Jan 8, 2025 | 
clinicaltrialsarena.com | Eve Thomas
Hong Kong-based Insilico Medicine has announced positive results from two Phase I studies of ISM5411 (NCT06012578), a novel gut-restricted and prolyl hydroxylase domain (PHD)-specific inhibitor designed and optimised using the company’s AI platform Chemistry42. The drug is being considered for the treatment of inflammatory bowel disease (IBD) and was nominated as a preclinical candidate for the illness in January 2022.
-
Jan 7, 2025 | 
medicaldevice-network.com | Eve Thomas
The cardiovascular devices market is set to grow at a compound annual rate (CAGR) of 5.2% between 2023 and 2033, with AI set to both push and diversify the market, according to a GlobalData analyst. Cynthia Stinchcombe, medical devices analyst at GlobalData, told Medical Devices Technology: “The cardiovascular devices market is undergoing rapid expansion and diversification.
